Integrating platelet reactivity in the age, creatinine and ejection fraction score to predict clinical outcomes following percutaneous coronary intervention in patients with chronic coronary syndrome: the PR-ACEF score.

IF 1.4 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Heart and Vessels Pub Date : 2024-06-24 DOI:10.1007/s00380-024-02430-5
Luca Paolucci, Fabio Mangiacapra, Michele Mattia Viscusi, Sara Sergio, Edoardo Bressi, Iginio Colaiori, Elisabetta Ricottini, Ilaria Cavallari, Annunziata Nusca, Rosetta Melfi, Gian Paolo Ussia, Francesco Grigioni
{"title":"Integrating platelet reactivity in the age, creatinine and ejection fraction score to predict clinical outcomes following percutaneous coronary intervention in patients with chronic coronary syndrome: the PR-ACEF score.","authors":"Luca Paolucci, Fabio Mangiacapra, Michele Mattia Viscusi, Sara Sergio, Edoardo Bressi, Iginio Colaiori, Elisabetta Ricottini, Ilaria Cavallari, Annunziata Nusca, Rosetta Melfi, Gian Paolo Ussia, Francesco Grigioni","doi":"10.1007/s00380-024-02430-5","DOIUrl":null,"url":null,"abstract":"<p><p>To evaluate if integrating platelet reactivity (PR) evaluation in the original age, creatinine and ejection fraction (ACEF) score could improve the diagnostic accuracy of the model in patients with stable coronary artery disease (CAD). We enrolled patients treated with percutaneous coronary intervention between 2010 and 2011. High PR was included in the model (PR-ACEF). Co-primary end points were a composite of death/myocardial infarction (MI) and major adverse cardiovascular events (MACE). Overall, 471 patients were enrolled. Compared to the ACEF score, the PR-ACEF showed an improved diagnostic accuracy for death/MI (AUC 0.610 vs 0.670, p < 0.001) and MACE (AUC 0.572 vs 0.634, p < 0.001). These findings were confirmed using internal validation with bootstrap resampling. At 5 years, the PR-ACEF value > 1.75 was independently associated with death/MI [HR 3.51, 95% CI (1.97-6.23)] and MACE [HR 2.77, 95% CI (1.69-4.53)]. The PR-ACEF score was effective in improving the diagnostic performance of the ACEF score at the long-term follow-up.</p>","PeriodicalId":12940,"journal":{"name":"Heart and Vessels","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Heart and Vessels","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00380-024-02430-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

To evaluate if integrating platelet reactivity (PR) evaluation in the original age, creatinine and ejection fraction (ACEF) score could improve the diagnostic accuracy of the model in patients with stable coronary artery disease (CAD). We enrolled patients treated with percutaneous coronary intervention between 2010 and 2011. High PR was included in the model (PR-ACEF). Co-primary end points were a composite of death/myocardial infarction (MI) and major adverse cardiovascular events (MACE). Overall, 471 patients were enrolled. Compared to the ACEF score, the PR-ACEF showed an improved diagnostic accuracy for death/MI (AUC 0.610 vs 0.670, p < 0.001) and MACE (AUC 0.572 vs 0.634, p < 0.001). These findings were confirmed using internal validation with bootstrap resampling. At 5 years, the PR-ACEF value > 1.75 was independently associated with death/MI [HR 3.51, 95% CI (1.97-6.23)] and MACE [HR 2.77, 95% CI (1.69-4.53)]. The PR-ACEF score was effective in improving the diagnostic performance of the ACEF score at the long-term follow-up.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
将血小板反应性纳入年龄、肌酐和射血分数评分,预测慢性冠状动脉综合征患者经皮冠状动脉介入治疗后的临床结果:PR-ACEF 评分。
目的是评估在原始年龄、肌酐和射血分数(ACEF)评分中加入血小板反应性(PR)评估是否能提高模型对稳定型冠状动脉疾病(CAD)患者的诊断准确性。我们招募了 2010 年至 2011 年期间接受经皮冠状动脉介入治疗的患者。高 PR 被纳入模型(PR-ACEF)。共同主要终点为死亡/心肌梗死(MI)和主要不良心血管事件(MACE)的复合终点。共有 471 名患者入选。与 ACEF 评分相比,PR-ACEF 对死亡/心肌梗死的诊断准确性有所提高(AUC 0.610 vs 0.670,p 1.75),PR-ACEF 评分与死亡/心肌梗死[HR 3.51,95% CI (1.97-6.23)]和 MACE [HR 2.77,95% CI (1.69-4.53)]独立相关。在长期随访中,PR-ACEF评分能有效改善ACEF评分的诊断性能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Heart and Vessels
Heart and Vessels 医学-外周血管病
CiteScore
3.10
自引率
13.30%
发文量
211
审稿时长
2 months
期刊介绍: Heart and Vessels is an English-language journal that provides a forum of original ideas, excellent methods, and fascinating techniques on cardiovascular disease fields. All papers submitted for publication are evaluated only with regard to scientific quality and relevance to the heart and vessels. Contributions from those engaged in practical medicine, as well as from those involved in basic research, are welcomed.
期刊最新文献
Acknowledgement to reviewers. Transaortic and transfemoral stent deployment approaches related morphological and clinical outcomes after type II hybrid arch repair for type A aortic dissection. 5-Aminolevulinic acid combined with ferrous iron ameliorates myocardial ischemia/reperfusion injury by increasing heme oxygenase-1. Evaluation of ventricular repolarization in dermatomyositis and relationship with inflammation and autoimmunity. Evaluation of acute thrombus regression effect of edoxaban for deep vein thrombosis in patients with cancer: a single-center prospective observational study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1